U.S. Markets open in 7 hrs 20 mins

Colchicine Market To Reach USD 1.13 Billion By 2026| Reports And Data

Colchicine Market Size – USD 553.8 Million in 2018, CAGR of 9.3%, Colchicine Industry Trends – Wider application range of the drug

New York, Jan. 27, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Colchicine market was valued at USD 553.8 million in 2018 and is expected to reach USD 1.13 billion by the year 2026, at a CAGR of 9.3%. Colchicine is an alkaloid drug preferably used in the treatment of an attack of gout. Gout is usually characterized by joint pain and inflammation and is caused when an excess of uric acid gets accumulated in joints in the form of needle-like crystals in a joint. Gout is nothing but a critical case of inflammatory arthritis. Increasing incidences of arthritis across the globe and the rising global burden of gout are the major driving factors enhancing the market growth. Arthritis is the primary cause of disability, pain, and ultimately loss of work potential irrespective of age group. In 2017 approximately 54.4 million (25% of the population) American adults diagnosed with arthritis prominently osteoarthritis, rheumatoid arthritis, gout, lupus, and fibromyalgia were constantly growing, and is expected to reach 78 million (26% of the population) the U.S. adults. The rising pace of aging across the globe is rising joint-related disorders such as joint pain, and gouty arthritis is estimated to enhance the growth of colchicine.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2374

Various field players are engaged in developing new application range of the colchicine. For instance, Pharmascience Inc. introduced colchicine application in the prevention of myocardial infarction (MI). Various market players are engaged in modifying the colchicine structure by combining with carriers such as borneol-chemically-modified colchicine ethosome that showed better transdermal activity over the traditional drug formulation in the treatment of inflammation. Growing usage of colchicine in various industries such as veterinary and agriculture is expected to increase the market growth. For example, colchicine is expected to enhance quality traits in ornamental plants. It acts as a mitotic inhibitor for the induction of polyploidy in plants leading to quality trait of flower. However, allergic reactions caused due to colchicine may hinder market growth.

Further key findings from the report suggest

  • Various government organization are engaged in developing the application of colchicine in variety of diseased conditions. For instance, National Institute of Child Health and Human Development in collaboration with National Institute of Diabetes and Digestive and Kidney Diseases and National Heart, Lung, and Blood Institute is developing application of the drug in Non-Diabetic Adults with Metabolic Syndrome
  • Favorable funding scenario in the respective industry is expected to be one of the major factor propelling market. For instance, ZonMw (The Netherlands Organisation for Health Research and Development), the Netherlands Heart Foundation, the Australian National Health and Medical Research Council and generic pharma were engaged in developing the colchicine use in medical conditions such as coronary artery disease and other cardiovascular conditions
  • Various industry players are focusing on expanding the client reach through various marketing strategies. For instance, Par Pharmaceutical, Inc. (Par) one of the operating company of Endo International plc has started distributing generic version of Takeda Pharmaceutical's Colcrys (colchicine, USP) 0.6 mg tablets in the U.S. market
  • During 2019-2026, colchicine market is expected to register a CAGR of 9.9% in Asia Pacific; followed by North America and Europe, with 9.7% and 9.2% CAGR, respectively. High prevalence of gout and related diseases across the globe is the major factor driving the market during the forecast period across all regions.
  • The tablet form of colchicine segment dominates the field with highest market share in the year 2018. It is estimated to grow at a CAGR of 9.3% during the forecast period to reach USD 358.07 million by 2026
  • Based on application segment, acute gout is expected to account for the CAGR 9.7% of the global colchicine market, as increased demand of masking the odor and taste of the molecule used and to provide sustained release effect
  • Asia Pacific is expected to account for the CAGR 9.9% of the global colchicine market. Developing nations such China, and India are likely to witness high growth due to high prevalence of diseases, increased healthcare expenditure and growing R&D investment
  • Based on end use adults dominate the total market share of colchicine, as the adults are high prevalent to gout and arthritis followed by geriatric population worldwide
  • Allergic reaction encountered due to colchicine use, and availability of alternative treatment options are among the key factors likely to hamper growth of the colchicine market
  • Key participants include Abbott Laboratories, Hikma Pharmaceuticals, Cipla Limited, West Ward Pharmaceutical, Takeda Pharmaceuticals America, Inc., Cardinal Health, Major Pharmaceuticals, Excellium Pharmaceutical, Mylan Pharmaceuticals Inc., Odan Laboratories

To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/colchicine-market

Segments covered in the report:

For the purpose of this report, Reports and Data has segmented the colchicine market on the basis of dosage formulation, application, end use and region:                     

Dosage Formulation Outlook (Revenue, USD Million; 2016-2026)

  • Tablet
  • Capsule
  • Solution
  • Cream
  • Injection
  • Others

Application Outlook (Revenue, USD Million; 2016-2026)

  • Acute Gout
  • Chronic Gout
  • Familial Mediterranean Fever
  • Gout Prophylaxis
  • Actinic Keratosis
  • Amyloidosis
  • Behcet's Disease
  • Pericarditis
  • Pseudogout
  • Dermatitis Herpetiformis
  • Paget's Disease
  • Biliary and Hepatic Cirrhosis
  • Others

End Use Outlook (Revenue, USD Million; 2016-2026)

  • Pediatric
  • Adult
  • Geriatric

Order Now: https://www.reportsanddata.com/checkout-form/2374

Regional Outlook (Revenue in USD Billion; 2016–2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Latin America
  • Brazil

Browse more similar reports on Biotechnology category by Reports And Data

In vivo CRO Market - https://www.reportsanddata.com/report-detail/in-vivo-cro-market

Cell Surface Markers Market - https://www.reportsanddata.com/report-detail/cell-surface-markers-market

Gene Expression Market - https://www.reportsanddata.com/report-detail/gene-expression-market

Blue Light Therapy Market - https://www.reportsanddata.com/report-detail/blue-light-therapy-market

Neuroprosthetics Market - https://www.reportsanddata.com/report-detail/neuroprosthetics-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:
John Watson
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-800-819-3052
E-mail: sales@reportsanddata.com